BIOGEN INC. Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months
BIOGEN INC. (BIIB) had Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months of $26.80 million as of 2018-12-31, per its 10-K filed 2020-02-06.
Discontinued › Notes › Leases
us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear · last filed 2020-02-06
- 2018-12-31: Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months $26.80M.
- 2017-12-31: Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months $24.30M.
- 2016-12-31: Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months $8.90M.
- 2015-12-31: Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months $6.00M.
| Period end | Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months |
|---|---|
| 2018-12-31 | $26.80M 10-K · filed 2020-02-06 |
| 2017-12-31 | $24.30M 10-K · filed 2018-02-01 |
| 2016-12-31 | $8.90M 10-K · filed 2017-02-02 |
| 2015-12-31 | $6.00M 10-K · filed 2016-02-03 |
| 2014-12-31 | $5.60M 10-K · filed 2015-02-04 |
| 2013-12-31 | $0.00 10-K · filed 2014-02-06 |
| 2012-12-31 | $500.00K 10-K · filed 2013-02-05 |
| 2011-12-31 | $500.00K 10-K · filed 2012-02-03 |
| 2010-12-31 | $400.00K 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |